Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
This guide introduces Zero Based Budgeting For Financial Success, explaining how to assign every dollar and align spending with your financial goals.
22,155 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Novo Nordisk has drifted toward a five-year low, raising questions about value vs. risk. This guide breaks down the f...
Bill Ackman's closed-end fund recently trades at a sizable discount, prompting questions about a Berkshire-style bet....
Axsome Therapeutics stock keeps climbing, hitting another high as regulatory news and a solid quarterly update bolste...
Investors have long looked to deals to jumpstart Netflix's growth. Five paraphrased lines from Netflix's co-CEO revea...
Pfizer faced a post-pandemic revenue shift, but the 2026 landscape still offers income and defensive upside. This gui...
A major fund is doubling down on Lionsgate Studios as shares skyrocket. Learn what know about this bet, the strategy ...
Intuitive Machines has captured investor attention as space missions gain traction. This guide breaks down the main d...
Could Lilly ride a Nvidia-like surge? This piece analyzes whether the stock can follow Nvidia’s AI-driven momentum, f...
Market curiosity about the hottest upcoming IPOs is at an all-time high. This guide explains how to gain exposure bef...
In the AI boom, everyone chase chips and models. But the most important company you've probably never heard of sits b...
SpaceX aims to push humanity beyond Earth, and its IPO could redefine tech investing. This guide breaks down how mult...